Hematologic Oncology Update

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T...

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)Ongoing Pha...

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:

Introduction (0:00)New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:...

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)Richter Transformation (30:43)Selection and Sequencing of Therapies for Relapsed/Refracto...

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from...